Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "preclinical"

309 News Found

SPARC announces submission of IND Application for SBO-154 to USFDA
News | April 04, 2025

SPARC announces submission of IND Application for SBO-154 to USFDA

The IND application supports the next phase of development of SBO-154


Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
News | March 13, 2025

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD


Zydus and Gates Foundation to develop world’s first combination vaccine to offer protection against shigellosis and typhoid
News | March 04, 2025

Zydus and Gates Foundation to develop world’s first combination vaccine to offer protection against shigellosis and typhoid

Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine


Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
News | February 27, 2025

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies


Veeda Group rebrands as Veeda Lifesciences
News | January 03, 2025

Veeda Group rebrands as Veeda Lifesciences

The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise


Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist
News | January 01, 2025

Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist

Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535


IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors
News | December 31, 2024

IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors

Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)


SVU to organise International Conference on Clinical Translation of Biomaterial-based Therapeutics and Devices on 6-7 Feb, 2025
News | December 26, 2024

SVU to organise International Conference on Clinical Translation of Biomaterial-based Therapeutics and Devices on 6-7 Feb, 2025

The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”


Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease
Biotech | December 07, 2024

Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease

GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization